Drug interactions
NUMBER OF RECORDS LOCATED =    31
 

Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug
Mahmood I and Sahajwalla C
Clinical Pharmacokinetics Apr 1999;36(4):277-287
A review of this subject under the following headings: analytical methods;
pharmacokinetics of buspirone; pharmacokinetics of buspirone in special
populations; drug interactions; conclusions. (48 refs.)



Pharmacokinetics and potential interactions amongst antiretroviral agents used
to treat patients with HIV infection
Barry M et al.
Clinical Pharmacokinetics Apr 1999;36(4):289-304
A review of this subject under the following headings: overview of
antiretroviral drugs; nucleoside reverse transcriptase inhibitors; protease
inhibitors; non-nucleoside reverse transcriptase inhibitors; conclusion. (101
refs.)



Severe ergotism associated with interaction between ritonavir and ergotamine
Liaudet L et al.
British Medical Journal 20 Mar 1999;318:771
Report of a 28 year old woman on anti-HIV combination therapy including
ritonavir 600mg/12h who developed severe ergotism after taking 3mg ergotamine
over 5 days.  Ritonavir is a potent inhibitor of CYP3A4, which is responsible
for the metabolism of ergot.  Any administration of ergot alkaloids should be
discontinued when ritonavir treatment is started in patients with HIV
infection. (5 refs.)



In vitro metabolic interaction studies: Experience of the Food and Drug
Administration
Yuan R et al.
Clinical Pharmacology & Therapeutics Jul 1999;66:9-15
A total of 194 new molecular entities approved by the US Food and
Administration between 1992 and 1997 were surveyed to determine the role of in
vitro metabolic interactions in the conduct of drug-drug interaction studies
and to examine the methods used in these studies.  Approximately 30% of the
submissions were found to have in vitro metabolism-based interaction studies,
most of which were inhibitory in nature.  Chemical inhibition was the most
commonly used approach in studying drug interactions in vitro.  In this
article, an attempt to assess the quality of the chemical inhibition approach
is made.  Four areas were found to be often overlooked: (1) incubation time and
concentration of the drug, (2) the difference between inhibition constant (ki)
and 50% inhibitory concentration (IC50) values, (3) the substrate-dependent
inhibition potential, and (4) the metabolic genotype or phenotype of the liver
donor.




Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and
intravenous midazolam
Palkama VJ et al.
Clinical Pharmacology & Therapeutics Jul 1999;66:33-39



Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral
doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male
volunteers
Wittke B et al.
British Journal of Clinical Pharmacology May 1999;47(5):521



Signalling possible drug-drug interactions in a spontaneous reporting system:
delay of withdrawal bleeding during concomitant use of oral contraceptives and
itraconazole
van Puijenbroek EP et al.
British Journal of Clinical Pharmacology Jun 1999;47(6):689



The effect of bosentan on the pharmacokinetics of digoxin in healthy male
subjects
Weber C et al.
British Journal of Clinical Pharmacology Jun 1999;47(6):701



Loss of blood pressure control on withdrawal of fluconazole during nifedipine
therapy
Kremens B et al.
British Journal of Clinical Pharmacology Jun 1999;47(6):707 (letter)



Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor
metabolizers
Ko JW et al.
Clinical Pharmacology & Therapeutics Jun 1999;65(6):606-614



Quantitative drug interactions prediction system (Q-DIPS): a computer-based
prediction and management support system for drug metabolism interactions
Bonnabry P et al.
European Journal of Clinical Pharmacology Jul 1999;55(5):341-347



Multidrug resistance modulation in vivo: The effect of cyclosporin A alone or
with dexverapamil on idarubicin pharmacokinetics in acute leukemia
Pea F et al.
European Journal of Clinical Pharmacology Jul 1999;55(5):361-368




Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo
Teilmann Larsen J et al.
European Journal of Clinical Pharmacology Jul 1999;55(5):375-382



Pharmacokinetic interactions between microemulsion formulated cyclosporine A
and diltiazem in renal transplant recipients
Asberg A et al.
European Journal of Clinical Pharmacology Jul 1999;55(5):383-387



Grapefruit juice has no effect on quinine pharmacokinetics
Ho PC et al.
European Journal of Clinical Pharmacology Jul 1999;55(5):393-398



The effect of cimetidine on the steady-state pharmacokinetics and
pharmacodynamics of warfarin in humans
Niopas I et al.
European Journal of Clinical Pharmacology Jul 1999;55(5):399-404



Grapefruit juice increases the bioavailability of artemether
van Agtmael MA et al.
European Journal of Clinical Pharmacology Jul 1999;55(5):405-410



Radiopharmacy: the role of the pharmacist
Palmer M
Hospital Pharmacist Feb 1999;6(2):38-41
Discussion of the role of the pharmacist as a member of the nuclear medicine
team in a hospital. (5 refs.)



Safety issues concerning the use of disulfiram in treating alcohol dependence
Chick J
Drug Safety May 1999;20(5):427-435
A review of the literature discussing the adverse effects of disulfiram, and
its interaction with alcohol and other drugs.  The risks and consequences of
intentional overdosage, and the association of disulfiram usage with developing
lung cancer are also discussed. (50 refs.)




The treatment of advanced prostate cancer with ketoconazole: safety issues
Bok RA and Small EJ
Drug Safety May 1999;20(5):451-458
A review looking at the biochemistry of ketoconazole and the rationale for its
use in prostate cancer.  Adverse effects of, and drug interactions with,
ketoconazole are also discussed. (38 refs.)



Clinical pharmacokinetics and pharmacodynamics of bromfenac
Skjodt NM and Davies NM
Clinical Pharmacokinetics Jun 1999;36(6):399-408
A literature review. (31 refs.)



Drug interactions with tobacco smoking: an update
Zevin S and Benowitz NL
Clinical Pharmacokinetics Jun 1999;36(6):425-438
A literature review. (128 refs.)



Antiretroviral drug guidelines for the treatment of HIV infection: should
protease inhibitors always be included in the initial regimen or not?
Churchill D and Weber J
BioDrugs Mar 1999;11:147-153
Combination antiretroviral therapy, usually consisting of two nucleoside
analogue reverse transcriptase inhibitors and a protease inhibitor (PI), has
revolutionised the management of patients with HIV infection.  PI-containing
combinations are significantly superior to combinations of two nucleoside
analogues, and the latter combination is now indicated only in very exceptional
circumstances.  However, the emerging longer term toxicity associated with PIs
and, to a lesser extent, problems with long term adherence to complex regimens
make the use of 'protease-sparing' regimens attractive.  Although such regimens
may be associated with a lower chance of sustained suppression of viral load,
leading to the development of drug resistance and virological rebound, they
allow the preservation of whole class of antiretrovirals for later use, avoid
the risk of PI toxicity, and can also help to avoid drug interactions
associated with PIs.



Drug interactions, renal impairment and hypoglycaemia in a patient with Type II
diabetes
Collin M and Mucklow JC
British Journal of Clinical Pharmacology Aug 1999;48(2):134-137



Induction of zidovudine glucuronidation and amination pathways by rifampicin in
HIV-infected patients
Gallicano KD et al.
British Journal of Clinical Pharmacology Aug 1999;48(2):168-179




The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of
(R/S)-verapamil in humans
Sandstrom R et al.
British Journal of Clinical Pharmacology Aug 1999;48(2):180-189



The effects of moclobemide on the pharmacokinetics of the 5-HT 1B/1D agonist
rizatriptan in healthy volunteers
van Haarst AD et al.
British Journal of Clinical Pharmacology Aug 1999;48(2):190-196



Hypoglycemia associated with high doses of sertraline and sulphonylurea
compound in a noninsulin-dependent diabetes mellitus patient
Takhar J and Williamson P
Canadian Journal of Clinical Pharmacology Spring 1999;6(1):12-14
A patient with schizoaffective disorder with noninsulin-dependent diabetes
mellitus treated with sertraline, risperidone and glyburide who developed
hypoglycaemia is presented.  Greater inhibition of the P450 system was likely
induced at doses higher than those recommended.  This process was reversed
within 10 days of discontinuing the sertraline.  Good glycaemic control
followed discontinuation of psychotropic drugs and the oral hypoglycaemic
agent.



A possible tetracycline-risperidone-sertraline interaction in an adolescent
Steele M and Couturier J
Canadian Journal of Clinical Pharmacology Spring 1999;6(1):15-17
A 15-year-old adolescent male, with Asperger's disorder, Tourette's disorder
and obsessive-compulsive disorder, on a tetracycline-risperidone-sertraline
treatment regimen, had an acute exacerbation of motor and vocal tics.  The
increase in tics may have resulted from either a tetracycline-risperidone
interaction leading to decreased levels of risperidone, or a
tetracycline-sertraline interaction leading to increased levels of sertraline
or the natural course of the Tourette's disorder.  The sertraline dose was
increased with no concomitant increase in tics, and the subsequent
discontinuation of tetracycline resulted in an improvement in tics, which
indicates an interaction between tetracycline and risperidone.  The addition of
antibiotics to psychotropic medications require close monitoring due to the
potential interactions.



Topiramate : increasing the choice for patients with refractory partial
epilepsy
Drugs & Therapy Perspectives 2 Aug 1999;14(3):1-5
Review under the headings - effective in partial seizures, shows promise in
Lennox-Gastaut syndrome, adverse events usually self-limiting, most drug
interactions minor, a cost-effective option, and prescribing and formulary
considerations.  Includes differential features table for topiramate vs
carbamazepine vs gabapentin vs tiagabine. (18 refs., 1994-99)




Levalbuterol for asthma
Medical Letter 4 Jun 1999;41(1054):51-53
Sepracor (levalbuterol - Xopenex
The FDA have approved the R-isomer of racemic salbutamol, for use with a
nebuliser, for the prevention and treatment of bronchospasm in patients.
Aspects briefly discussed include: pharmacology, pharmacokinetics, clinical
trials, adverse effects, drug interactions and dosage.  Authors conclude that
it appears to have no clinically significant advantage over racemic salbutamol.